Inmunoterapia en cáncer de vejiga - page 14

Published online March 4, 2016
•
Impressive ORR/OS in IC3 population
•
Responses maintained on time
•
Good safety profile in a fragile population
•
Results consistent over time [ESMO 2016]
•
Possible TCGA groups association
•
Who will benefit the most ?
1...,4,5,6,7,8,9,10,11,12,13 15,16,17,18,19,20,21,22,23,24,...36
Powered by FlippingBook